Number of the records: 1  

Glycogen as an advantageous polymer carrier in cancer theranostics: straightforward in vivo evidence

  1. 1.
    SYSNO ASEP0525299
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleGlycogen as an advantageous polymer carrier in cancer theranostics: straightforward in vivo evidence
    Author(s) Gálisová, A. (CZ)
    Jirátová, M. (CZ)
    Rabyk, Mariia (UMCH-V) RID, ORCID
    Sticová, E. (CZ)
    Hájek, M. (CZ)
    Hrubý, Martin (UMCH-V) RID, ORCID
    Jirák, D. (CZ)
    Article number10411
    Source TitleScientific Reports. - : Nature Publishing Group - ISSN 2045-2322
    Roč. 10, č. 1 (2020), s. 1-11
    Number of pages11 s.
    Languageeng - English
    CountryGB - United Kingdom
    Keywordsglycogen ; polymers ; drug delivery system
    Subject RIVCD - Macromolecular Chemistry
    OECD categoryPolymer science
    R&D ProjectsLTC19032 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
    GA18-07983S GA ČR - Czech Science Foundation (CSF)
    Method of publishingOpen access
    Institutional supportUMCH-V - RVO:61389013
    UT WOS000545967200008
    EID SCOPUS85086831274
    DOI10.1038/s41598-020-67277-y
    AnnotationAs a natural polysaccharide polymer, glycogen possesses suitable properties for use as a nanoparticle carrier in cancer theranostics. Not only it is inherently biocompatible, it can also be easily chemically modified with various moieties. Synthetic glycogen conjugates can passively accumulate in tumours due to enhanced permeability of tumour vessels and limited lymphatic drainage (the EPR effect). For this study, we developed and examined a glycogen-based carrier containing a gadolinium chelate and near-infrared fluorescent dye. Our aim was to monitor biodistribution and accumulation in tumour-bearing rats using magnetic resonance and fluorescence imaging. Our data clearly show that these conjugates possess suitable imaging and tumour-targeting properties, and are safe under both in vitro and in vivo conditions. Additional modification of glycogen polymers with poly(2-alkyl-2-oxazolines) led to a reduction in the elimination rate and lower uptake in internal organs (lower whole-body background: 45% and 27% lower MRI signals of oxazoline-based conjugates in the liver and kidneys, respectively compared to the unmodified version). Our results highlight the potential of multimodal glycogen-based nanopolymers as a carrier for drug delivery systems in tumour diagnosis and treatment.
    WorkplaceInstitute of Macromolecular Chemistry
    ContactEva Čechová, cechova@imc.cas.cz ; Tel.: 296 809 358
    Year of Publishing2021
    Electronic addresshttps://www.nature.com/articles/s41598-020-67277-y
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.